Circulating mRNA expression of CD133, SNAIL, ZEB1 and ZHX as biomarkers in gastric and esophageal cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter F. Longo Muñoz
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors F. Longo Muñoz1, J. Earl2, J. Martinez Avila3, M. Rodriguez Garrote1, C. Guerrero2, J. Galindo2, P. Priego2, G. Rodriguez2, F. García-Moreno2, F. Lopez2, A. Hervás2, A. Caminoa2, I. García2, C. Soteras2, E. Vázquez-Sequeiros2, J. Botella2, V. Pachón Olmos1, R. Ferreiro Monteagudo1, M. Vaz2, A. Gómez2, C. Guillén-Ponce4, A. Carrato5
  • 1Ramón y Cajal University Hospital, Madrid, Spain, /
  • 2Hospital Universitario Ramón y Cajal, Madrid, Spain, /
  • 3Hospital Universitario 12 de Octubre, Madrid, Spain, /
  • 4H. Universitario Ramón y Cajal, IRYCIS, Madrid, Spain, /
  • 5Hospital Ramón y Cajal, Madrid, Spain, /


Patients diagnosed with gastric and esophageal adenocarcinoma (GEA) have a poor prognosis despite curative treatment with multimodal treatment including surgery, chemotherapy (CT) and radiotherapy (RT). CD133, SNAIL and ZEB1 have shown to provide additional prognostic information in advanced GEA patients. ZHX dysfunction is associated with poor prognosis in cancer.